Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00026442
Recruitment Status : Unknown
Verified April 2004 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : January 27, 2003
Last Update Posted : December 18, 2013
Information provided by:
National Cancer Institute (NCI)

November 9, 2001
January 27, 2003
December 18, 2013
November 2001
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00026442 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Capecitabine in Treating Women With Advanced or Metastatic Breast Cancer
A Pilot Trial Of Two Different Doses Of Capecitabine (XELODA) In Patients With Advanced And/Or Metastatic Breast Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Randomized phase II trial to compare the effectiveness of two different doses of capecitabine in treating women who have advanced or metastatic breast cancer.


  • Compare the objective response rate in women with advanced or metastatic breast cancer treated with two dose levels of capecitabine.
  • Compare the duration of response, time to progression, time to treatment failure, survival, incidence of adverse events, and time to onset of the adverse experience in patients treated with this drug.
  • Compare the quality of life of patients treated with this drug.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to Karnofsky performance status (70-80% vs 90-100%) and presence of hepatic metastases (yes vs no). Patients are randomized to one of two treatment arms.

  • Arm I: Patients receive lower-dose oral capecitabine twice daily on days 1-14.
  • Arm II: Patients receive higher-dose oral capecitabine twice daily on days 1-14.

In both arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, at the end of the third and sixth courses, and at completion of therapy.

PROJECTED ACCRUAL: A total of 120 patients (60 per treatment arm) will be accrued for this study within 9 months.

Phase 2
Primary Purpose: Treatment
Breast Cancer
Drug: capecitabine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Not Provided
Not Provided
Not Provided
Not Provided


  • Histologically and/or cytologically confirmed breast cancer
  • Advanced and/or metastatic disease
  • At least 1 measurable lesion

    • At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
  • No CNS metastases
  • Hormone receptor status:

    • Not specified



  • 18 and over


  • Female

Menopausal status:

  • Not specified

Performance status:

  • Karnofsky 70-100%

Life expectancy:

  • At least 12 weeks


  • Neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3


  • Bilirubin no greater than 1.25 times upper limit of normal (ULN)
  • AST/ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present)
  • Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN if liver metastases present OR 10 times ULN if bone metastases present)
  • No hepatitis


  • Creatinine no greater than 1.5 times ULN
  • Creatinine clearance at least 50 mL/min


  • No clinically significant cardiac disease
  • No congestive heart failure
  • No symptomatic coronary artery disease
  • No cardiac arrhythmias poorly controlled with medication
  • No myocardial infarction within the past 12 months even if adequately controlled with medication


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No severe pain inadequately controlled by analgesics
  • No prior severe and unexpected reaction to fluoropyrimidine therapy
  • No known hypersensitivity to fluorouracil
  • No impaired physical integrity of the upper gastrointestinal tract
  • No malabsorption syndrome
  • No inability to swallow tablets
  • No history of uncontrolled seizures, central nervous system disorder, or psychiatric disability that would preclude study participation
  • No serious uncontrolled infection


Biologic therapy:

  • Not specified


  • At least 2 but no more than 3 prior chemotherapy regimens
  • At least 1 prior chemotherapy regimen containing paclitaxel and an anthracycline as adjuvant therapy or for advanced and/or metastatic disease

Endocrine therapy:

  • Not specified


  • No prior radiotherapy to target lesions unless there is evidence of new disease within the irradiated field
  • No concurrent radiotherapy


  • No prior organ allografts


  • At least 4 weeks since prior investigational drug
  • No concurrent enrollment on other investigational study
  • No other concurrent anticancer agents
Sexes Eligible for Study: Female
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
Pharmatech Oncology
Not Provided
Study Chair: Sandy Marcus Pharmatech Oncology
National Cancer Institute (NCI)
April 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP